NasdaqGS:BRKRLife Sciences
Assessing Bruker (BRKR) Valuation After New FDA Claims And Mass Spectrometry Launches
Bruker (BRKR) stock is in focus after the company used ASM Microbe 2026 to spotlight new FDA-backed capabilities for its MALDI Biotyper CA System, alongside broader launches in diagnostics and ultra-high-resolution mass spectrometry.
See our latest analysis for Bruker.
Recent news around new diagnostics capabilities and conference appearances comes as Bruker’s share price has pulled back 6% in the last day and 4% over the week, after a strong 52% 3 month share price return and 48% 1 year...